Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Market Cap	13.91T +12.9%
Revenue (ttm)	1.26T +7.5%
Net Income	434.01B +12.1%
EPS	263.72 +12.1%
Shares Out	1.65B
PE Ratio	32.05
Forward PE	27.44
Dividend	132.00 (1.56%)
Ex-Dividend Date	Dec 29, 2025

Volume	2,409,500
Average Volume	2,288,805
Open	8,529.00
Previous Close	8,451.00
Day's Range	8,344.00 - 8,553.00
52-Week Range	5,942.00 - 10,700.00
Beta	0.46
RSI	40.41
Earnings Date	Apr 24, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,872
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.